JP2022529743A5 - - Google Patents
Info
- Publication number
- JP2022529743A5 JP2022529743A5 JP2021563213A JP2021563213A JP2022529743A5 JP 2022529743 A5 JP2022529743 A5 JP 2022529743A5 JP 2021563213 A JP2021563213 A JP 2021563213A JP 2021563213 A JP2021563213 A JP 2021563213A JP 2022529743 A5 JP2022529743 A5 JP 2022529743A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- nmosd
- product according
- administered
- aforementioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025120173A JP2025157413A (ja) | 2019-04-24 | 2025-07-17 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838093P | 2019-04-24 | 2019-04-24 | |
| US62/838,093 | 2019-04-24 | ||
| US201962843096P | 2019-05-03 | 2019-05-03 | |
| US62/843,096 | 2019-05-03 | ||
| US201962858495P | 2019-06-07 | 2019-06-07 | |
| US62/858,495 | 2019-06-07 | ||
| PCT/US2020/029613 WO2020219743A2 (en) | 2019-04-24 | 2020-04-23 | Use of an anti-cd19 antibody to treat autoimmune disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120173A Division JP2025157413A (ja) | 2019-04-24 | 2025-07-17 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529743A JP2022529743A (ja) | 2022-06-23 |
| JP2022529743A5 true JP2022529743A5 (https=) | 2023-09-14 |
| JP7779738B2 JP7779738B2 (ja) | 2025-12-03 |
Family
ID=72940915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563213A Active JP7779738B2 (ja) | 2019-04-24 | 2020-04-23 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
| JP2025120173A Pending JP2025157413A (ja) | 2019-04-24 | 2025-07-17 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120173A Pending JP2025157413A (ja) | 2019-04-24 | 2025-07-17 | 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220204617A1 (https=) |
| EP (1) | EP3959241A4 (https=) |
| JP (2) | JP7779738B2 (https=) |
| KR (1) | KR20220004113A (https=) |
| CN (1) | CN113939532A (https=) |
| AU (1) | AU2020263418A1 (https=) |
| BR (1) | BR112021020924A2 (https=) |
| CA (1) | CA3136487A1 (https=) |
| IL (1) | IL287385A (https=) |
| MX (1) | MX2021012870A (https=) |
| SG (1) | SG11202111429UA (https=) |
| WO (1) | WO2020219743A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3809260A1 (de) * | 2019-10-18 | 2021-04-21 | Siemens Healthcare GmbH | System und verfahren zur administration von bildgebenden geräten |
| WO2022006283A2 (en) * | 2020-06-30 | 2022-01-06 | Viela Bio, Inc. | Methods of treating neuromyelitis optica spectrum disorder |
| AU2021368769A1 (en) * | 2020-10-29 | 2023-06-08 | Viela Bio, Inc. | Use of an anti-cd19 antibody to treat autoimmune disease |
| IL308296A (en) * | 2021-05-07 | 2024-01-01 | Viela Bio Inc | Use of anti-CD19 antibody to treat myasthenia gravis |
| CN119604305A (zh) | 2022-07-27 | 2025-03-11 | 维埃拉生物股份有限公司 | 伊奈利珠单抗及使用其用于持续b细胞耗竭的方法 |
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534859B (zh) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| RU2495882C2 (ru) * | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| MX2014010987A (es) * | 2012-03-12 | 2015-03-03 | Medimmune Llc | Tratamiento de esclerosis multiple con anticuerpo anti-cd19. |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
-
2020
- 2020-04-23 AU AU2020263418A patent/AU2020263418A1/en active Pending
- 2020-04-23 JP JP2021563213A patent/JP7779738B2/ja active Active
- 2020-04-23 CA CA3136487A patent/CA3136487A1/en active Pending
- 2020-04-23 WO PCT/US2020/029613 patent/WO2020219743A2/en not_active Ceased
- 2020-04-23 US US17/606,306 patent/US20220204617A1/en active Pending
- 2020-04-23 KR KR1020217038068A patent/KR20220004113A/ko active Pending
- 2020-04-23 EP EP20794203.8A patent/EP3959241A4/en active Pending
- 2020-04-23 CN CN202080030819.6A patent/CN113939532A/zh active Pending
- 2020-04-23 MX MX2021012870A patent/MX2021012870A/es unknown
- 2020-04-23 BR BR112021020924A patent/BR112021020924A2/pt unknown
- 2020-04-23 SG SG11202111429UA patent/SG11202111429UA/en unknown
-
2021
- 2021-10-19 IL IL287385A patent/IL287385A/en unknown
-
2025
- 2025-07-17 JP JP2025120173A patent/JP2025157413A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529743A5 (https=) | ||
| Strupp et al. | The treatment and natural course of peripheral and central vertigo | |
| O'Duffy et al. | Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease | |
| Akman-Demir et al. | Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? | |
| JP7185426B2 (ja) | Ｓ１ｐ受容体モジュレーターの投与計画 | |
| Allen et al. | A prospective study of 32 patients with neurosarcoidosis | |
| Fragoso et al. | Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years | |
| Hauser et al. | Benzodiazepine withdrawal delirium with catatonic features: occurrence in patients with partial seizure disorders | |
| US20250188158A1 (en) | Treatment of Parkinson's Disease | |
| Lopalco et al. | Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis | |
| Kaur et al. | Optic neuritis and the neuro‐ophthalmology of multiple sclerosis | |
| Saha | Vertigo related to central nervous system disorders | |
| Ndiaye et al. | Cochleovestibular impairment in pediatric Cogan’s syndrome | |
| Namiranian et al. | Neuromuscular complications of systemic amyloidosis | |
| US20230406928A1 (en) | Methods of treating neuromyelitis optica spectrum disorder | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| JP2023549075A5 (https=) | ||
| Miralles et al. | Pure sensory Guillain-Barré syndrome | |
| JP2024540294A5 (https=) | ||
| Algahtani et al. | A novel mutation in CACNA1A gene in a Saudi female with episodic ataxia type 2 with no response to acetazolamide or 4-aminopyridine | |
| Arshi et al. | The first rapid onset optic neuritis after measles–rubella vaccination: case report | |
| Ascaso et al. | Visual field defects in pediatric patients on vigabatrin monotherapy | |
| Haase et al. | Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis | |
| RU2021134020A (ru) | Применение антитела к cd19 для лечения аутоиммунного заболевания | |
| Mack et al. | Acute anterior uveitis in a patient taking fingolimod (FTY720) for multiple sclerosis |